Imugene Receives A$11.7 Million R&D Tax Refund
Imugene Receives A$11.7 Million R&D Tax Refund | ASX:IMU, OTC:IUGNF
Imugene Ltd: Imugene Receives $11.7m R&D Tax Refund
Why Cettire, Gold Road, Imugene, and Paladin Energy Shares Are Racing Higher
First Aussie Doses Bring Imugene Major Step Closer to 'Quicker, Cheaper' Non-Hodgkin's Lymphoma Care
Guess Which ASX Small Cap Stock Is Jumping on 'Significant Milestone'
Imugene Says First Australian Patient Dosed in Lymphoma Trial
ASX Preview: Australian Shares to Open Lower Amid Wall Street Losses
Imugene Receives Substantial Capital Injection; Extends Cash Runway to End of 2025 in Support of Ongoing Trials
Imugene to Raise AU$46 Million in Convertible Notes, Warrants Issue
Imugene to Receive A$11 Million R&D Tax Refund for FY23 | ASX:IMU, OTC:IUGNF
6 ASX Shares Down 50%+ in 2024. Are They Cheap?
Imugene Doses First Patient in Intratumoral Injection Group of Phase 1 Cancer Trial
Five at Five AU: ASX to End Week on a High Note | ASX:IMU, OTC:IUGNF
Why Imugene, Neuren, Sigma, and Smartgroup Shares Are Charging Higher
Imugene Opens First Australian Site for Azer-cel Clinical Trial Targeting Lymphoma | ASX:IMU, OTC:IUGNF
Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources Shares Are Charging Higher
Guess Which ASX 300 Stock Is Jumping 11% on Big News
Imugene VAXINIA Achieves Complete Response in Patient Two Years After Bile Tract Cancer Treatment
Imugene VAXINIA Achieves Complete Response in Patient Two Years After Bile Tract Cancer Treatment | ASX:IMU, OTC:IUGNF